anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A toothpaste tablet, comprising a binding agent, an abrasive agent, a whitening agent, a polishing agent, a sulfate free surfactant, natural gum, sweetener, and a flavour agent. Preferably, the composition further comprises sodium fluoride. Preferably, the abrasive is one of sodium bicarbonate or magnesium stearate. Preferably, the polishing agent is either hydrated silica or sodium hydrogen carbonate. The sweetener may be stevia, sorbitol or xylitol. The binding agent may be cellulose or sorbitol. Also claimed is a toothpaste tablet for use in brushing a subject’s teeth, comprising: a binding agent in an amount ranging from about 20% to 95% by weight, a surfactant at 1.0% to 10% by weight, an abrasive at 0.1% to 30% by weight, and an artificial sweetener in an amount ranging from about 0.5% to 75% by weight. Further claimed is a method of making a toothpaste tablet for use in brushing a subject’s teeth, and a method of cleaning a subject’s teeth comprising chewing the toothpaste tablet as described herein.
Participants were administered 35 mg/m²/dose of FTD/TPI orally BID, within 1 hour after completion of morning and evening meals, 5 days on (Day 1 to 5 and Day 8 to 12) with 2 days off (Day 6 to 7 and Day 13 to 14), over 2 weeks, followed by a 14-day rest. This treatment cycle was repeated every 4 weeks.
The invention discloses a traditional Chinese medicine for promoting hair growth and conditioning hair, which is characterized in that the traditional Chinese medicine is prepared by 7 traditional Chinese medicine raw materials that are longhairy antenoron herb, sweet potato leaf, and mango, etc. with the parts by weight. Each selected medicine has positive effect for treating baldness; furthermore, each medicine is very common, edible, non-toxic and cheap. The traditional Chinese medicine is used for treating a plurality of cases with baldness over the past few years, which has no other adverse reactions or side effects. The medicine can lead the people with baldness to grow the hair by low cost and simple procedure within a short period of time, thus changing the grass to forest, returning to the original appearance and beauty of the people and eliminating the trouble and suffering. The medicine composition, the production process and the treatment method are simple and convenient, the cost is low, and the treatment effect of baldness is significant.
Commercially, many microdissection needle systems are available, such as Stryker Colorado® microdissection needle (CMN) (Stryker-Leibinger, Freiburg, Germany) and optimicro™ microdissection needles. Colorado® microdissection needle (CMN) combine the advantages of scalpel and electrosurgery. CMN® was introduced into clinical practice in 1997, with a wide array of applications in the field of Ophthalmology, Neurosurgery, and others.

The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain. The instrument tip is a delicately machined, insulated tungsten diathermy needle that is compatible with any standard cautery hand piece. Tungsten, with its extremely high melting point (\>3400°C) provides a heat resistant tip that maintains sharpness compared to stainless steel tips that dull rapidly.
Nausea, vomiting, lethargy, tachycardia, bradycardia, asystole, cardiac arrest, hypotension, syncope, hypocalcemia, metabolic acidosis, and death have been reported in cases of overdosage with CEREBYX.

Because CEREBYX is a prodrug of phenytoin, the following information about phenytoin overdosage may be helpful. Initial symptoms of acute phenytoin toxicity are nystagmus, ataxia, and dysarthria. Other signs include tremor, hyperreflexia, lethargy, slurred speech, nausea, vomiting, coma, and hypotension. Death is caused by respiratory and circulatory depression. The lethal dose of phenytoin in adults is estimated to be 2 to 5 grams. The lethal dose in pediatrics is not known.

There are marked variations among individuals with respect to serum phenytoin concentrations where toxicity occurs. Lateral gaze nystagmus usually appears at 20 µg/mL, ataxia at 30 µg/mL, and dysarthria and lethargy appear when the serum concentration is over 40 µg/mL. However, phenytoin concentrations as high as 50 µg/mL have been reported without evidence of toxicity. As much as 25 times the therapeutic phenytoin dose has been taken, resulting in serum phenytoin concentrations over 100 µg/mL, with complete recovery. Irreversible cerebellar dysfunction and atrophy have been reported after overdosage.

Formate and phosphate are metabolites of CEREBYX and therefore may contribute to signs of toxicity following overdosage. Signs of formate toxicity are similar to those of methanol toxicity and are associated with severe anion-gap metabolic acidosis. Large amounts of phosphate, delivered rapidly, could potentially cause hypocalcemia with paresthesia, muscle spasms, and seizures. Ionized free calcium levels can be measured and, if low, used to guide treatment.

Treatment: Treatment is nonspecific since there is no known antidote to CEREBYX or phenytoin overdosage.

The adequacy of the respiratory and circulatory systems should be carefully observed, and appropriate supportive measures employed. Hemodialysis can be considered since phenytoin (the active metabolite of CEREBYX) is not completely bound to plasma proteins. Total exchange transfusion has been used in the treatment of severe intoxication in children.

In acute overdosage the possibility of other CNS depressants, including alcohol, should be borne in mind.
A particle includes a complex between a bioactive agent and a complexing agent, provided that the bioactive agent is other than a polynucleotide and an oligonucleotide, and wherein the particle has a bioactive function. The particle has a diameter from about 5 nm to about 100 microns. In certain embodiments, the bioactive agent is a member selected from the group consisting of a growth factor, a hormone, a peptide, a protein, and polysaccharide. In certain embodiments, the complexing agent is a member selected from the group consisting of polysaccharides, glycosaminoglycans, complex carbohydrates, polyacids, modifications and derivatives thereof. Also provided is a method of making the particle. Further provided is a method of administering the particle, including providing the particle, which is adapted to gradually release the bioactive agent; and thereby administering the particle.
Participants received 375 mg/m2 rituximab i.v. weekly for 4 weeks; and 3 million international units per day (MIU/day) interferon-a2a subcutaneously (s.c.) during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5. Interferon-a2a was not administered on days of rituximab administration. Participants achieving MR, PR, or CR received a second cycle of treatment.
During the operation, necessary interventions were made by following the algorithm. Hemodynamic and mechanical ventilation parameters of patients were recorded 5 minutes after induction, 30 minutes after pneumoperitoneum and at the end of surgery and were performed arterial blood gas analysis.
The invention relates to a compound ear drop for treating otitis externa mycotica, in particular to an ear drop for treating otitis externa mycotica. The drop is prepared by the the following ingredients: 3-30g of fluconazol, 5-50g of tinidazole, 3-30g of menthol, 100-800g of glycerine, 30-200ml of alcohol, 5-100ml of 1mol/L sodium hydroxide solution, and 1000ml of distilled water. The drop contains both antifungal drug and antianaerobic drug which enable the ear drop to have both antifungal activity and antianaerobic activity. In the process of preparation allocation, the tinidazole being slightly soluble into water need be heated by aqueous bath to be dissolved, the fluconazol and the menthol are easily dissolved into the alcohol. The alcohol is used for not only dissovling both the fluconazol and the menthol, but also being taken a transdermal accelerant of the ear drop, as well as drying the external acoustic meatus. The menthol can dispel wind to make the skin and the membrana mucosa cool and relieve the complaint and pain. A fixed amount of glycerine can protect the ear mucosa and keep the preparation tensile and adhesive.
Compositions containing an anti-acne effective amount of five components that work combinatorially to combat the acne condition as a whole. The composition contains anti-irritant, anti-inflammatory, adhesion inhibiting, sebum reducing and sclareolide components. Inflamed and non-inflamed lesions associated with acne are reduced with a combination of the anti-irritant component, the anti-inflammatory component comprising at least hoelen mushroom extract, the adhesion inhibiting component comprising at least a polysaccharide, the sebum reducing component comprising at least a pygeum extract, and the sclareolide component. Methods of the present invention treat acne holistically. Therefore, these methods treat and prevent the irritation and inflammation frequently experienced when applying acne treatment. By applying to the skin an effective amount of the composition of the present invention the appearance of comedones is prevented. Compositions of the present invention protect against damaging effects of acne, and the appearance of comedones and pustules.
PROBLEM TO BE SOLVED: To make it possible to discharge at always adequate amt. of cosmetics and to use these cosmetics by making the narrowest flow passage diameters of the cosmetics in a fixed volume discharge container larger than the diameter of the collapsible particles contained in the cosmetics containing the collapsible particles and housed and contained in the container. SOLUTION: The working parts of check valves 13a, 13b are merely the narrowest parts and the route diameters of these narrowest parts are freely settable according to the pump container 100 having a horizontal push type pump 10. For example, the setting of the diameters at 1000 to 5000μm is easy. Then, the particle size range of the collapsible particles contained in the liquid cosmetics to be discharges is settable at a range of about 100 to 1000μm. The viscosity range adequate for the liquid cosmetics for discharging the liquid cosmetics without crushing the particles is settable at a range of about 1000 to 100000cPs. The good discharging of the liquid cosmetics from the discharge port 14 is possible even if the liquid cosmetics are of a high viscosity like jell- like materials.
Studies have shown that the microbiota-gut-brain axis is highly correlated with the pathogenesis of depression in humans. However, whether independent oral microbiome that do not depend on gut microbes could affect the progression of depression in human beings remains unclear, neither does the presence and underlying mechanisms of the microbiota-oral-brain axis in the development of the condition. Hence this study that encompasses clinical and animal experiments aims at investigating the correlation between oral microbiota and the onset of depression via mediating the microbiota-oral-brain axis. We compared the oral microbial compositions and metabolomes of 87 patients with depressive symptoms versus 70 healthy controls. We found that the oral microbial and metabolic signatures were significantly different between the two groups. Significantly, germ-free (GF) mice transplanted with saliva from mice exposing to chronic restraint stress (CRS) displayed depression-like behavior and oral microbial dysbiosis. This was characterized by a significant differential abundance of bacterial species, including the enrichment of Pseudomonas, Pasteurellaceae, and Muribacter, as well as the depletion of Streptococcus. Metabolomic analysis showed the alternation of metabolites in the plasma of CRS-exposed GF mice, especially Eicosapentaenoic Acid. Furthermore, oral and gut barrier dysfunction caused by CRS-induced oral microbiota dysbiosis may be associated with increased blood-brain barrier permeability. Pseudomonas aeruginosa supplementation exacerbated depression-like behavior, while Eicosapentaenoic Acid treatment conferred protection against depression-like states in mice. These results suggest that oral microbiome and metabolic function dysbiosis may be relevant to the pathogenesis and pathophysiology of depression. The proposed microbiota-oral-brain axis provides a new way and targets for us to study the pathogenesis of depression.
Embodiments of the invention control a device based on physiological measurements associated with a user. A determination is made that a user has manually adjusted a controlled device. A context associated with the user is identified in response to determining that the user has manually adjusted the controlled device. A change is detected in at least one physiological measurement associated with the user in response to the controlled device being manually adjusted. A target physiological measurement associated with at least one physiological measurement is modified based on the change that has been detected. The context that has been identified is associated with the target physiological measurement that has been modified.
FIELD: medicine. SUBSTANCE: described is new 2,4-disulfo-alpha-phenyl- tert-butylnitron compound of formula I and pharmaceutically acceptable salts thereof. These compounds are useful as pharmaceutical agents for parenteral, e.g. intraveous injection to patients suffering from acute oxidation of central nervous system which occurs during shock, or from gradual oxidation of central nervous system. These agents are also useful for weakening intensity of side effects in treating diseases which cause oxidative disorder. Also described are pharmaceutical composition and methods of medical treatment using compounds of general formula I. EFFECT: improved properties of the pharmaceutical composition and more efficient medical treatment methods. 22 cl, 14 ex, 6 tbl
OBJECTIVE: Endometriosis is associated with a range of symptoms that can negatively impact a person's quality of life. While pain and infertility have received at lot of attention, sleep disturbances in individuals with endometriosis has been overlooked in both clinical practice and research. Therefore, the primary aim of this systematic review was to gather evidence from the current literature to illustrate the association between sleep disturbances and endometriosis.
STUDY DESIGN: A literature search was conducted using three electronic databases (OVID EMBASE, MEDLINE, and Web of Science). Observational studies, published in English, that involved participants aged 18 years or older that compared sleep outcomes between endometriosis patients and those without a history of endometriosis were included. The quality of each study was assessed using the Joanna Briggs Institute critical appraisal tools.
RESULTS: Nine studies (six case-control and three cross-sectional) were included in this review; 7 with low risk of bias and 2 with moderate risk of bias. The studies demonstrated heterogeneity in the assessment of sleep disturbances. However, 7 studies reported a significant positive association between endometriosis and sleep disturbances. Moreover, this impact on sleep was further complicated by the complex interaction between pain, fatigue and quality of life.
CONCLUSION: Current studies suggest an association between sleep disturbances and endometriosis, which may provide a blueprint for future clinical recommendations to screen and treat sleep disturbances in individuals with endometriosis to improve their quality of life. Future studies should aim to standardise the methods of assessing sleep disturbances and explore potential contributing factors.
* Deferasirox Oral Granules, 90 mg is supplied in cartons containing 30 child-resistant foil sachets. Each sachet contains 132.5 mg of white to off white granules, equivalent to 90 mg deferasirox.
  * Deferasirox Oral Granules, 180 mg is supplied in cartons containing 30 child-resistant foil sachets. Each sachet contains 265 mg of white to off white granules, equivalent to 180 mg deferasirox.
  * Deferasirox Oral Granules, 360 mg is supplied in cartons containing 30 child-resistant foil sachets. Each sachet contains 530 mg of white to off white granules, equivalent to 360 mg deferasirox.
FIELD: biotechnology, medicine, medicinal microbiology. SUBSTANCE: invention relates to the strain of lactobacillus of species Lactobacillus acidophilus that can be used for preparing fermented-milk curative-dietetic foodstuffs. The strain Lactobacillus acidophilus N.V. Ep 317/402-X (author name is "Balans- Narine") is obtained by selection of the parent culture Lactobacillus acidophilus N.V. Ep 317/402 "Narine" and directed selection by the following indices: -antagonistic activity relative to microorganisms causing gastroenteric diseases, in part, pathogenic bacteria Helicobacter pylori causing different forms of gastritis and stomach and duodenum ulcers; - ability to produce useful substances (vitamins, amino acids, antioxidants); - resistance of bacterial cell membrane structures to external effects (acidity, temperature and so on) providing retention of lactobacilli high titer in the storage process. The strain Lactobacillus acidophilus shows more broad spectrum of antagonistic activity, in part, relative to pathogenic bacteria Helicobacter pylori causing different forms of gastritis and stomach and duodenum ulcers and significantly more content of useful substances that are necessary for correction of dysbacteriosis and different gastroenteric diseases. EFFECT: valuable medicinal properties of strain and fermented-milk product. 4 tbl, 5 ex
The low AGE diet will be the same as the standard diet in terms of calories (i.e. 30-35 kcal/kg/day) and protein (0.75-0.84 g/kg/day). However, it will reduce the dietary AGE content by changing cooking methods in food preparation to avoid exposure to dry heat such as frying, broiling, grilling and roasting, and to favour cooking with lower temperatures and high-water content as in stewing, steaming, boiling and poaching. In addition, the low-AGE group will be instructed to choose foods with low content of AGEs based on a food choice list that will contain examples of foods commonly available in the UK to be chosen as "allowed," "moderate intake," or "occasional." The goal will be to reduce dietary AGE intake to less than 8000 kU/day.
The identification of the cause of primary aldosteronism (PA) is critical because, in case of lateralized secretion of aldosterone, a surgical treatment can be offered to patients with the objective of full patient recovery, whereas in case of bilateral secretion, only a long-term medical treatment with mineralocorticoid receptor antagonists should be considered. The presence or absence of adrenal nodule on morphological imaging does not allow us to state on the lateralization or not of aldosterone secretion. Moreover, on one hand, the prevalence of adrenal incidentalomas, mostly non-secreting, can be detected in between 2 to 10% of general population. On the other hand, unilateral secretion of aldosterone exists in 30% of patients with normal adrenal glands on imaging. The AVS with measurements of the concentrations of aldosterone is the closest to a referral exam to confirm the diagnosis of lateralized secretion of aldosterone, but it is a complex and invasive procedure with only limited access to centers with expertise in invasive radiology and an important heterogeneity in interpretation. The development of noninvasive imaging approaches allowing for a more specific identification of lateralized vs. bilateral aldosterone secretion would, hence, have a major impact on the clinical management of these patients.
Rationale: The drug combination called CHOP, or Cyclophosphamide (Cytoxan), Doxorubicin (Adriamycin), Vincristine (Oncovin), and Prednisone (Deltasone), has been used against different types of lymphoma for many years. Researchers are investigating what other therapies to combine with the CHOP regimen to improve outcomes for patients with lymphoma. The current study combines CHOP with alemtuzumab, a monoclonal antibody used against leukemia. Monoclonal antibodies are a type of immunotherapy used against some types of cancer. They are produced in a laboratory and designed to target as well as bind with cells that carry specific proteins. Alemtuzumab is designed to target leukemia cells that express a specific protein. The specific protein recognized by alemtuzumab is the CD52 antigen. This antigen, or substance that causes the immune system to create a specific response, is expressed on normal B and T cells, as well as on abnormal T cells characteristic of certain cancers. Alemtuzumab causes the CD52 antigen to bind with B-cell lymphocytes. This study will also assess the theory that alemtuzumab may increase the effectiveness of the chemotherapy agents included in the CHOP regimen.

Treatment: Patients in this study will receive alemtuzumab and CHOP. Alemtuzumab will be given through injections into the skin and CHOP will be administered through intravenous infusions. Patients will receive alemtuzumab alone during the first week of the study. An increasing amount of alemtuzumab will be given during the first week. If patients cannot tolerate the highest amount of alemtuzumab determined as appropriate within one week, they will be removed from the study. Once the highest dose of alemtuzumab has been achieved, patients will then receive both alemtuzumab and CHOP every three weeks. This schedule will be repeated up to eight times. Several tests and exams will be given throughout the study to closely monitor patients. Treatments will be discontinued due to disease growth or unacceptable side effects.
Blount disease, also known as pathologic tibia vara , is an acquired growth disorder of the medial proximal tibial physis and epiphysis that results in a three-dimentional deformity of the lower limb (a progressive varus ,procurvatum and internal rotaion deformity of the tibia). Blount disease can be classified as infantile, or early onset form, which appears before the age of four years, juvenile, which appears between four and ten years and adolescent, or late onset form, which appears in children older than ten years. Surgical treatment options include tibial osteotomies with either acute or gradual correction and proximal lateral tibial hemiepiphysiodesis (guided growth) the latter being less invasive and with significantly lower rate of major complications. Guided growth by 8 plate hemiepiphysiodesis is commonly used to correct coronal plane deformity around the knee. Since its introduction by Stevens in 2007 many studies have demonstrated the efficacy, safety and advantages of tension band plating in the paediatric age group as an alternative to corrective osteotomy. The marked intoeing seen in Blount disease may be caused by internal tibial torsion, femoral anteversion or metatarsus adductus ..yet, there is no enough available literature studies evaluating the amount of correction of tortional deformity after coronal plane deformity correction by 8 plate hemiepiphysiodesis.

This is the question of this study and we are trying to answer it by measuring the torsional plane deformity after achieving full correction of coronal plane deformity by 8 plate hemiepiphysiodesis.
In this prospective study the investigators aim to quantify participants' responses to physical activity. Participants will be asked to engage in physical activity, to identify any provocation of symptoms in adolescents ranging from ages 10 to 22 years. Responses to physical activity will be measured through physiologic markers (e.g., blood pressure, heart rate, oxygen saturation, rate of perceived exertion, dyspnea). Additionally, participants will be monitored for any changes in symptoms that occur during or after physical activity as measured by the modified PCSS symptom inventory.